Member Info for chattty

It's evident from OF's latest podcast, which was released today, that there is a substantial level of interest and enthusiasm from the U.S. government for expediting the progress of GMET's Flagship Pilot Mountain Tungsten Project. This enthusiasm is driven by the project's advancements and the recognition of tungsten as a crucial and essential resource, particularly in light of the absence of domestic tungsten production in the USA. Notably, Pilot Mountain represents the only in-ground resource for tungsten in the country.

The rapid pace at which things are moving forward indicates positive developments, and when these are officially announced, it will boost the sp.

Regardless of how one interprets the RNS, it appears to unequivocally state that the company is not meeting the business forecasts they previously laid out.

This has led some to speculate negatively, suggesting that more adverse news may be on the horizon, especially considering the track record of the current leadership team, which has both new and old members.

The sp is demonstrating that negativity.

From the RNS 'We have also seen the consequences of a lull in customer confidence in the period leading up to completion of the £3.6 million fundraise, which means that the half-year revenue figure to 31 December 2023, will be less than the comparative period in 2022"

This RNS announcement is essentially a housekeeping move that will allow us to issue shares, particularly when the global market sentiment becomes more favorable for mining companies. It's becoming clear that market sentiment is changing due to the recognition of an impending output shortage resulting from ever-increasing demand, and it's highly unlikely that this demand can be fully met.

In the meantime, we have the anticipation of a million-dollar-plus payment and royalties to look forward to, along with potential Pozzolan-related news.

The announcement of funding success for GMET's primary Pilot Mountain project is anticipated to happen within a 6 to 9-month timeframe, with initial submissions having been made around June or July.

This timeline considers the submission of multiple funding applications fore ongoing efforts to support various project stages, ranging from development to production.

It's essential to emphasize that, despite POW holding a "controlling interest," they have not the authority to enforce changes desired by the CEO, SW, in this context.

The SII has continued to grow and has now reached an impressive 26 billion, a substantial figure. This progress is likely to pave the way for a consolidation, which would bring several advantages in significantly improving their financial stability, increase the market value of their shares, and make them more attractive to potential HNWs and IIs investors, ultimately leading to an increase in the share price.

Nice one ! Buy in !

"Safetrader" doesn't seem to share anyone elses enthusiasm for the current low stock price of this company as it stands as an attractive investment.

Those who are buying in now have a good chance of making profits in the near term, unlike Safetrader, who appears to have a consistent negative outlook likely influenced by their own past losses.

We all experience losses in the world of investments, but what's crucial is not dwelling on them and taking responsibility for our own decisions.

From Stockhead.Today 08:54

International majors downgrade earnings as lithium pullback hits refiners

A surprising read.

newsletter@stockhead.com.au

International majors downgrade earnings as lithium pullback hits refiners

A surprising read.

newsletter@stockhead.com.au

I find that some people live in the past, constantly blaming others for their losses. I prefer not to dwell on old news but focus on what's ahead. The last time the price went up decent profits were made.

This time, the buy-in is lower, so I believe that before or around Christmas, the stock price should increase, as there are more reasons to be optimistic. There is also a gradual recognition of a forward price movements in rare earths and similar commodities. This because industrialists worldwide are realizing the need for more investments to meet increasing demand, which is set against a shortage of manufacturing and supply in the world.

SRES assets will get part of that recognition.

Childish to say the least.

Spanish company Tolsa S.A. are the world's largest producer of sepiolite, has an option to purchase the Pioche Project for $1.25 million by December 28, 2023.

SRES will will also receive a 3% revenue royalty on production from the entire project area.

After successfully completing a drilling program, Tolsa and SRES are moving forward to draft a definitive option agreement as per the existing binding option agreement.

The 3% royalty will provide a steady income to the company.

Not forgetting Pozzolan news last issued on 15th sept.,-"The Company is currently waiting for a bulk sample from its Hazen natural pozzolan project to be test ground in a commercial grinding mill by an existing producer of natural pozzolan. It is also discussing joint development of its CS Natural pozzolan Project with three companies. One, a large cement and ready-mix group, has successfully completed an extensive programme of testwork. The second is a materials company that is currently undertaking its own testwork programme on CS natural pozzolan. The third is a cement company that is just starting its evaluation of the project."

It would be surprising if the existing low share price didn't increase in the short period of 8 weeks leading up to December 28, 2023, due to expected news regarding these transactions.

XxPro-To answer your question my basic opinion regarding a fund raise is it would be well-received due to the substantial information and ongoing activities supporting it.

Fundraising backed by a robust rationale and a plan for utilization, can be seen as a positive move by investors and the market especially where DP is concerned.

I am not suggesting a fund raise is required now or later.

As Van2000 suggests time is a factor especially for the share price if news expectations are not met.

It appears that some may not fully grasp the concept that i'm highlighting, where considering the potential for a share issue is merely a point for consideration rather than a concrete statement.

The answer you mentioned states, "I cannot think of any Strategic option," can be seen as definitive and potentially closes off that particular perspective.

With regard to your last paragraph -https://www.equitydevelopment.co.uk/research/xf-73-is-the-real-deal.

Scroll down the first page and basics will be seen under Summary Financials.

ATB

I do not apologize for any previous misunderstanding in my responses.

Thank you for your clarification. You made a valid point about considering buying shares based on the potential for positive news to impact the stock price.

As to any fund raising you appear not to understand the sentence 'The suggestion regarding a potential fund raise as a strategic option is noteworthy nothing more.'

End.

End.

Amid derogatory comments about the Board of Directors, it's important to remember that old news becomes outdated.

The primary concern is whether a profit can be generated from the confirmed assets. The assets that the company is dealing with are expected to become newsworthy before the end of the year, potentially changing the landscape and outlook for investors with regard to the sp.

Equity brokers- notes . Indicate that Destiny Pharma's cash position for 2024E is around £1.795 million. The suggestion regarding a potential fund raise as a strategic option is noteworthy nothing more. always

It does not mean to say it will happen

Few if any Board of Directors will explicitly rule out the possibility of raising funds, leaving room for strategic decisions in the future, despite the company's promising prospects.

Recent extensive publicity around Destiny Pharma has generated speculation regarding the company's future. This attention has led to two main speculations: either the company is preparing to raise funds or is on the verge of a significant deal. Nevertheless it's essential to recognize that the pharmaceutical industry typically involves lengthy negotiation processes for the rights to produce and market products, making an imminent deal less likely.

Destiny Pharma currently has 95 million shares in circulation and a cash runway expected to last until the end of 2024, but this could be extended with a fund raise. Given the tightness in cash markets and investor funding constraints, this might be a strategic move. Despite all the attention the share price looks like continuing its gradual decline, reflecting the complex and multifaceted market dynamics.

The Destiny stock price (sp) has experienced a decline from its recent high of 64p, now residing in the low 50p region. This may be attributed to the recognition that, following the flurry of news about XF-73, there will likely be a scarcity of updates due to the extended time frame involved in pharmaceutical negotiations for distribution and sales rights etc.,.

Notably, in June/July, the sp was considerably lower, in the 20/30p range, highlighting the price volatility of this stock. If no significant news emerges over the next six months (which is unlikely), there's a possibility the sp could revisit those lower price levels.

While it's currently expected that the sp should be moving toward at least £1 based on a valuation of £3 per share, the recent swift drop may push it even lower, possibly toward 40/50p. It may be prudent to wait before considering an entry point.

A potential catalyst for a sp surge would be positive news regarding a deal.

The reverse of course is news of a failure or delays , could lead to a sharp drop ("crash into DCB"). This underscores the volatile and unpredictable nature of stock movements, especially in the pharmaceutical sector.

Investor concerns center on Mr. Bell's leadership, characterized by a preference for high-risk jurisdiction assets that have a history of unfavorable results. This has raised doubts about his ongoing impact on investments. Investors must prudently evaluate their own investment strategy and risk tolerance, weighing the potential for alternative opportunities and divesting from assets associated with Mr. Bell if they find his approach discomforting. Given his track record, investing in this stock appears more like a speculative trade, with uncertain expectations for consistent delivery.

So for speculative traders only?